Data Sheet (Cat.No.T4473)

Ibiglustat

Chemical Properties

CAS No. :	1401090-53-6
Formula:	C20H24FN3O2S
Molecular Weight:	389.49
Appearance:	no data available
Storage:	Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.
Targets(IC50)	Transferase
In vitro	Ibiglustat is in phase II Clinical trials for the treatment of Fabry's disease. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy [1].

Solubility Information

Solubility	DMSO: 50 mg/mL (128.37 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5675 mL	12.8373 mL	25.6746 mL
5 mM	0.5135 mL	2.5675 mL	5.1349 mL
10 mM	0.2567 mL	1.2837 mL	2.5675 mL
50 mM	0.0513 mL	0.2567 mL	0.5135 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Schiffmann R, et al. Fabry disease. Handb Clin Neurol. 2015;132:231-48.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481